Zydus Cadila receives orphan drug status from USFDA for its novel malaria drug

Drug maker Cadila Healthcare (Zydus Cadila), on Thursday said its antimalarial drug ZY19489 (MMV253), currently in development together with Medicines for Malaria Venture (MMV), has received orphan drug designation from the USFDA.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3dWphrl
via IFTTT